These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36266091)

  • 21. On the Difference between a-priori and observed statistical power - A comment on "statistical power and sample size calculations: A primer for pediatric surgeons".
    Schröder A; Oetzmann von Sochaczewski C
    J Pediatr Surg; 2020 Jan; 55(1):203-205. PubMed ID: 31648778
    [No Abstract]   [Full Text] [Related]  

  • 22. Power and sample size.
    Case LD; Ambrosius WT
    Methods Mol Biol; 2007; 404():377-408. PubMed ID: 18450060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance, Errors, Power, and Sample Size: The Blocking and Tackling of Statistics.
    Mascha EJ; Vetter TR
    Anesth Analg; 2018 Feb; 126(2):691-698. PubMed ID: 29346210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size calculations in surgery: are they done correctly?
    Maggard MA; O'Connell JB; Liu JH; Etzioni DA; Ko CY
    Surgery; 2003 Aug; 134(2):275-9. PubMed ID: 12947329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Power to the People: Power, Negative Results and Sample Size.
    Gaskill BN; Garner JP
    J Am Assoc Lab Anim Sci; 2020 Jan; 59(1):9-16. PubMed ID: 31852563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Competing risks analysis of time-to-event data for cardiovascular surgeons.
    Staffa SJ; Zurakowski D
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2459-2466.e5. PubMed ID: 31866080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The experimental design of postmortem studies: the effect size and statistical power.
    Meurs J
    Forensic Sci Med Pathol; 2016 Sep; 12(3):343-9. PubMed ID: 27412160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assurance calculations for planning clinical trials with time-to-event outcomes.
    Ren S; Oakley JE
    Stat Med; 2014 Jan; 33(1):31-45. PubMed ID: 23861270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Power and Sample Size Calculations in Clinical Trials with Patient-Reported Outcomes under Equal and Unequal Group Sizes Based on Graded Response Model: A Simulation Study.
    Doostfatemeh M; Taghi Ayatollah SM; Jafari P
    Value Health; 2016; 19(5):639-47. PubMed ID: 27565281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focus on Data: Statistical Design of Experiments and Sample Size Selection Using Power Analysis.
    Ledolter J; Kardon RH
    Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):11. PubMed ID: 32645134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and analysis of factorial clinical trials: The impact of one treatment's effectiveness on the statistical power and required sample size of the other.
    Walter SD; Belo IJ
    Stat Methods Med Res; 2023 Jun; 32(6):1124-1144. PubMed ID: 37077125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simulation-based sample size calculations of marginal proportional means models for recurrent events with competing risks.
    Furberg JF; Andersen PK; Scheike T; Ravn H
    Pharm Stat; 2024 Mar; ():. PubMed ID: 38509020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sample-size calculations for studies with correlated ordinal outcomes.
    Kim HY; Williamson JM; Lyles CM
    Stat Med; 2005 Oct; 24(19):2977-87. PubMed ID: 16149125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical primer: sample size and power calculations-why, when and how?
    Hickey GL; Grant SW; Dunning J; Siepe M
    Eur J Cardiothorac Surg; 2018 Jul; 54(1):4-9. PubMed ID: 29757369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size determination in bioequivalence studies using statistical assurance.
    Ring A; Lang B; Kazaroho C; Labes D; Schall R; Schütz H
    Br J Clin Pharmacol; 2019 Oct; 85(10):2369-2377. PubMed ID: 31276603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size calculation for a stepped wedge trial.
    Baio G; Copas A; Ambler G; Hargreaves J; Beard E; Omar RZ
    Trials; 2015 Aug; 16():354. PubMed ID: 26282553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.